Welcome to Market Research Explore

Explore Market Research

Latest market research, industry analysis and market trend reports

Global Age Related Macular Degeneration Market 2018-2025

The global age related macular degeneration market is estimated to reach a market value of USD XX million by 2025 from an initial market value of USD 6,945.37 million in 2017. The global age related macular degeneration market is estimated to grow at a CAGR of 8.12% in the forecasted period 2018-2025. It is estimated that, there are around 2 million people in United States in 2017 are suffering with AMD with the patients for AMD are growing at a CAGR of 1.8% in US in the forecast period. It is estimated that more than 90% of the patients are suffering with dry AMD market with the rest 10% accounted by the wet AMD. Growing age-related eye diseases across the world, growing aged population, advancements in the technologies, and reimbursement benefits for the treatment are the major factors driving the growth of the market. Introduction of new drugs for the treatment of the wet age related macular degeneration market is also help in the growth of the market. Availability of alternative treatment options, high cost of treatments are the major factors restraining the growth of the market. “Increasing focus and spending by the companies on R & D on the development of new drugs will boost the growth of the market” The age related macular degeneration market is segmented by clinical trials, by drug type, by disease type, and by geography. Majority of the clinical trials are happening in United States, followed by China, Germany, Canada, France, and Australia. By Drug Type, Lucentis, Eylea, and Avastin accounts for more than 99% of the market share with rest all drugs accounting for less than 1% in 2017. It is estimated that sales of drugs Lucentis and Eylea accounted for around 5 billion in 2016. By geography, North America accounts for the largest market share in 2017 and is estimated to continue to dominate the market by the end of the forecast period 2025. The global age related macular degeneration market is segmented into: By drug type Lucentis Eylea Avastin Others By Disease type Dry AMD Wet AMD The global age-related macular degeneration market is a highly consolidated with four companies accounting for majority of the market share. There is a huge competition within the industry with companies focusing on development of new drugs. Partnerships and investments in R&D are the key strategies followed by the major companies in the industry Some of the major companies in global age related macular degeneration market include Novartis Roche Bayer Why purchase the report? Visualize the composition of the age related macular degeneration market across each indication, in terms of type and applications, highlighting the key commercial assets and players. Identify commercial opportunities in age related macular degeneration market by analyzing trends and co-development deals. Excel data sheet with thousands of data points of the age related macular degeneration market - level 4/5 segmentation PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study Product mapping in excel for the key age related macular degeneration market products of all major market players Target Audience Raw Material Suppliers/ Buyers Product Suppliers/ Buyers Industry Investors/Investment Bankers Education & Research Institutes Research Professionals Emerging Companies Manufacturers

1 Methodology and Scope 1.1 Research methodology 1.2 Scope of the Report 2. Headlines & Trends 2.1 Headlines 2.2 Key Trends & Developments 3. Industry Analysis 3.1 Market Drivers 3.2 Market Restraints 3.3 Porters Five Forces Analysis 3.3.1 Suppliers Power 3.3.2 Buyer Power 3.3.3 Industry Competition 3.3.4 Threat of new Entrant 3.3.5 Threat of Substitutes 4. Clinical Trial Analysis 4.1 By Age Group 4.1.1 Child 4.1.2 Adult 4.1.3 Senior 4.2 By Gender 4.2.1 Male 4.2.2 Female 4.3 By Study Phases 4.3.1 Early Phase 4.3.2 Phase 1 4.3.3 Phase 2 4.3.4 Phase 3 4.3.5 Phase 4 4.4 By Study Type 4.4.1 Interventional 4.4.2 Observational 5. Product Pipeline Analysis 6. Segmentation by Drug Type 6.1 Lucentis 6.2 Eylea 6.3 Avastin 6.4 Others 7. Segmentation by Disease Type 7.1 Dry AMD 7.2 Wet AMD 8. Segmentation by Treatment Type 8.1 Injecting Anti - vascular endothelial growth factor 8.2 photodynamic therapy 8.3 laser surgery 8.4 antibiotic drops 8.5 Others 9. Geographic Analysis 9.1 North America 9.1.1 United States 9.1.2 Canada 9.1.3 Mexico 9.1.4 Others 9.2 Europe 9.2.1 United Kingdom 9.2.2 Spain 9.2.3 Germany 9.2.4 France 9.2.5 Rest of Europe 9.3 Asia-Pacific 9.3.1 India 9.3.2 China 9.3.3 Australia 9.3.4 Japan 9.3.5 Rest of Asia-Pacific 9.4 South America 9.4.1 Brazil 9.4.2 Argentina 9.4.3 Rest of South America 9.5 Rest of the World 10. Competitive Landscape 10.1 Market Share Analysis 10.2 Company Benchmarking 10.3 Key Strategies Adopted by Major Companies 11. Company Profiles* 11.1 Bayer 11.2 Novartis 11.3 Roche 11.4 Bausch & Lomb 11.5 Allergan 11.6 Iconic Therapeutics 11.7 Neurotech Pharmaceuticals 11.8 Regeneron Pharmaceuticals Inc. 11.9 Alcon 11.10 Santen Pharmaceutical 12. Appendix 12.1 Sources 12.2 List of Charts 12.3 Expert Panel Validation 12.4 Disclaimer 12.5 Contact Us *Note: Additional company profiles will be included on request

  Payment Mode
Single User 3750
Corporate User 7250

  About this Report
Category Pharmaceutical
Published on 1/21/2019
Number of Pages 178
Over all Rating
"Rating is based on 71 reviews"